Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Development of Blood Vessels

Development of Blood Vessels

The development of the vascular system in a fetus is a complex and intricate process that begins as early as 15 to 16 days post-conception. This process starts outside the embryo, specifically in the mesoderm of the yolk sac, chorion, and connecting stalk. Approximately two days later, the formation of blood vessels occurs within the embryo itself.
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Elevated fetal middle cerebral artery peak systolic velocity caused by severe maternal anemia and reversed with maternal transfusion.

American journal of obstetrics and gynecology·2026

Same author

Maternal SARS-CoV-2 infection and early child growth and development: A nationwide cohort study.

The Journal of infection·2026

Same author

[Gynecology, Obstetrics and Fertility - Reborn in the Digital Revolution].

Harefuah·2026

Same author

[Types of Preeclampsia According to Placental Single Cell RNA Sequencing, Type 1 and Type 2 Levels - Insights and Clinical Implications].

Harefuah·2026

Same author

Management of fetal umbilical vein varix: a survey-based analysis of current clinical practice.

Archives of gynecology and obstetrics·2026

Same author

Fetal head station during artificial rupture of membranes: a large retrospective cohort study.

Frontiers in medicine·2025

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

An Ex Vivo Choroid Sprouting Assay of Ocular Microvascular Angiogenesis

An Ex Vivo Choroid Sprouting Assay of Ocular Microvascular Angiogenesis

Published on: August 6, 2020

Angiogenesis in gestational vascular complications.

¹Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Centers, Mt. Scopus, Jerusalem, Israel. simcha.yagel@gmail.com

Thrombosis Research

|January 26, 2011

Summary

Researchers discovered a new VEGF inhibitor, sFlt1-14, and found heparin and heparanase regulate soluble VEGF receptor (sFlt1) levels. This offers potential new treatments for preeclampsia by controlling sFlt1 release.

More Related Videos

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Published on: November 8, 2024

Kinetic Analysis of Vasculogenesis Quantifies Dynamics of Vasculogenesis and Angiogenesis In Vitro

Kinetic Analysis of Vasculogenesis Quantifies Dynamics of Vasculogenesis and Angiogenesis In Vitro

Published on: January 31, 2018

Related Experiment Videos

Last Updated: Jun 5, 2026

An Ex Vivo Choroid Sprouting Assay of Ocular Microvascular Angiogenesis

An Ex Vivo Choroid Sprouting Assay of Ocular Microvascular Angiogenesis

Published on: August 6, 2020

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Published on: November 8, 2024

Kinetic Analysis of Vasculogenesis Quantifies Dynamics of Vasculogenesis and Angiogenesis In Vitro

Kinetic Analysis of Vasculogenesis Quantifies Dynamics of Vasculogenesis and Angiogenesis In Vitro

Published on: January 31, 2018

Area of Science:

Reproductive biology
Vascular biology
Biochemistry

Background:

Vascular endothelial growth factor (VEGF) is crucial for blood vessel formation.
Soluble VEGF receptors, like sFlt1, regulate VEGF activity.
Imbalances in VEGF and sFlt1 are linked to preeclampsia.

Purpose of the Study:

To identify and characterize novel soluble VEGF receptors.
To investigate the regulation and bio-distribution of sFlt1.
To explore potential therapeutic targets for preeclampsia.

Main Methods:

Discovery and characterization of sFlt1-14, a novel soluble VEGF inhibitor.
Analysis of sFlt1 binding to heparin and its release from tissues.
In vivo studies using low molecular weight heparin (LMWH) and heparanase manipulation in mice and placental explants.

Main Results:

sFlt1-14 is a potent VEGF inhibitor produced by non-endothelial cells, notably vascular smooth muscle cells.
Increased sFlt1 in pregnancy, particularly in preeclampsia, is linked to sFlt1-14 expression.
sFlt1 binds strongly to heparin, and heparanase or LMWH can release sFlt1, increasing its circulation levels.

Conclusions:

sFlt1-14 represents a new player in VEGF regulation during pregnancy and preeclampsia.
Heparanase and LMWH influence sFlt1 bio-distribution by releasing it from heparin-bound sites.
Targeting heparanase or LMWH interactions may offer novel therapeutic strategies for preeclampsia.